Showing 1 - 5 results of 5 for search 'Renato G. Martins', query time: 0.04s Refine Results
  1. 1
    Docetaxel em administração semanal como quimioterapia de primeira linha para câncer de pulmão de não-pequenas células em estádio IV: tratamento eficaz com toxicidade baixa

    Docetaxel em administração semanal como quimioterapia de primeira linha para câncer de pulmão de não-pequenas células em estádio IV: tratamento eficaz com toxicidade baixa by Renato G. Martins, G. Advincula, R. Costa, B. Aragão, Waldelice Santos, Edson Toscano, Walter Roriz, Mauro Zamboni, Aureliano Sousa, Paulo de Biasi, Mauro Zukin

    Published 2004-12-01
    Get full text
    Article
  2. 2
    Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

    Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome by Perrin E. Romine, Renato G. Martins, Keith D. Eaton, Douglas E. Wood, Fatemeh Behnia, Bernardo H. L. Goulart, Michael S. Mulligan, Sarah G. Wallace, Elizabeth Kell, Julie E. Bauman, Shilpen A. Patel, Hubert J. Vesselle

    Published 2019-01-01
    Get full text
    Article
  3. 3
    Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

    Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors by Cassie Pan, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J. Houlton, Brittany Barber, Zain H. Rizvi, Emily Marchiano, Neal Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Renato G. Martins, Jonathan R. Fromm, Cristina P. Rodriguez

    Published 2023-04-01
    Get full text
    Article
  4. 4
    Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

    Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients by Cameron Chalker, Jenna M. Voutsinas, Qian Vicky Wu, Rafael Santana‐Davila, Victoria Hwang, Christina S. Baik, Sylvia Lee, Brittany Barber, Neal D. Futran, Jeffrey J. Houlton, George E. Laramore, Jay Justin Liao, Upendra Parvathaneni, Renato G. Martins, Keith D. Eaton, Cristina P. Rodriguez

    Published 2022-11-01
    Get full text
    Article
  5. 5
    Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

    Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chem... by Stephen R. Bowen, PhD, Daniel S. Hippe, MS, Hannah M. Thomas, PhD, Balukrishna Sasidharan, MBBS, MD, DNB, DMRT, Paul D. Lampe, PhD, Christina S. Baik, MD, MPH, Keith D. Eaton, MD, PhD, Sylvia Lee, MD, Renato G. Martins, MD, MPH, Rafael Santana-Davila, MD, Delphine L. Chen, MD, Paul E. Kinahan, PhD, Robert S. Miyaoka, PhD, Hubert J. Vesselle, MD, PhD, A. McGarry Houghton, MD, Ramesh Rengan, MD, PhD, Jing Zeng, MD

    Published 2022-03-01
    Get full text
    Article

Search Tools: